Modalis Therapeutics Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2018
Net Income	-2,151	-1,316	-2,390	-2,707	-745	Upgrade
Depreciation & Amortization	-	-	-	123	77	Upgrade
Loss (Gain) From Sale of Assets	2	-	38	997	2	Upgrade
Other Operating Activities	-	-15	1	1	488	Upgrade
Change in Accounts Payable	17	-119	49	9	51	Upgrade
Change in Other Net Operating Assets	14	18	48	-318	-620	Upgrade
Operating Cash Flow	-2,118	-1,432	-2,254	-1,895	-747	Upgrade
Capital Expenditures	-2	-	-39	-197	-107	Upgrade
Other Investing Activities	-	-	-	12	278	Upgrade
Investing Cash Flow	-2	-	-39	-185	171	Upgrade
Long-Term Debt Issued	493	694	488	-	-	Upgrade
Long-Term Debt Repaid	-500	-37	-	-	-	Upgrade
Net Debt Issued (Repaid)	-7	657	488	-	-	Upgrade
Issuance of Common Stock	1,367	2,395	735	71	72	Upgrade
Other Financing Activities	-9	-8	-7	-8	-	Upgrade
Financing Cash Flow	1,351	3,044	1,216	63	72	Upgrade
Foreign Exchange Rate Adjustments	7	79	27	14	17	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	1	-	2	Upgrade
Net Cash Flow	-762	1,691	-1,049	-2,003	-485	Upgrade
Free Cash Flow	-2,120	-1,432	-2,293	-2,092	-854	Upgrade
Free Cash Flow Margin	-	-	-	-5230.00%	-85400.00%	Upgrade
Free Cash Flow Per Share	-27.44	-31.05	-74.05	-71.87	-29.70	Upgrade
Cash Interest Paid	2	3	4	6	-	Upgrade
Cash Income Tax Paid	-	1	1	1	1	Upgrade
Levered Free Cash Flow	-1,411	-890.63	-1,418	-1,402	-787	Upgrade
Unlevered Free Cash Flow	-1,405	-885.63	-1,408	-1,399	-786.38	Upgrade
Change in Working Capital	31	-101	97	-309	-569	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.